View more on these topics

CellFactors breaks through via EIS

CellFactors is a company that aims to raise up to £3.5m through an enterprise investment scheme (EIS) for its human cell therapy projects.

The company says degenerate and dying cells cause conditions such as Parkinson&#39s disease, diabetes, cancer and heart disease. Human cell therapy can cure these problems through implanted cells, which can also help to repair broken bones.

The money raised by the EIS will be used for the commercial development of Skeletex, the company&#39s bone repair product which uses cartilage cells. Five orthopaedic companies are negotiating with CellFactors to license the product or help with its development.

The money will also be used to fund the expansion of NeuCell, a cell library which characterises human cells for the pharmaceutical industry and to help the company develop its cure for Parkinson&#39s disease.

The limited supply of foetal cells and the inability to control cells once they have been implanted into the body have hindered the progress of cell therapy in terms of marketing and regulation. But CellFactors believes it can overcome these issues by using a gene to create an unlimited supply of cells. The use of the gene, which is active only in laboratory conditions, also allows doctors to control the cells once they are implanted inside the body.

As an investment, this EIS is high risk as it invests in early stage medical advancements and further fundraising may be needed to get to the clinical trial stage. Following that, regulatory approval will be required. The prospectus says CellFactors is currently a loss-making company and this could mean investors may face a long wait to get a return on their investment, if any at all.

Recommended

Protection gap £13 billion says Swiss Re

UK insurers are under-insured against long-term ill health to the tune of £130 billion according to new figures from Swiss Re. The figure represents the difference between the amount of income protection held by UK insurers and the amount of insurance the working population should have. Swiss Re says only 20 per cent of the […]

Standard slams rivals on &#39manipulated&#39 FARs

Standard Life has hit out at rival insurers for manipulating free asset ratios while accepting that it has used new bases for calculating its own.Analyst Ned Cazalet has criticised Standard for using different criteria to calculate this year&#39s FAR despite admitting to an investment loss of £4bn.Standard&#39s FAR has increased to 8.9 per cent excluding […]

EIS to raise cash for new Capt Scarlet

Fund management group Margetts is helping to set up a production company under an Enterprise Investment Scheme to finance a new television series of kids&#39 favourite Captain Scarlet. The company – Gerry Anderson Productions – is seeking £15m to create 26 new episodes of the show, which was originally sold to more than 60 networks […]

Business up by 24% at Swiss Life

Swiss Life has reported an increase of 24 per cent in new business written during 2002, up to £53m from £42m in 2001. The provider says during the last year it enjoyed substantial growth in both critical illness and income protection sales. Managing director Brian Hurd says the fact IFAs have stuck with Swiss Life […]

Newsletter

News and expert analysis straight to your inbox

Sign up

Comments

    Leave a comment

    Close

    Why register with Money Marketing ?

    Providing trusted insight for professional advisers.  Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and advice.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm

    Email: customerservices@moneymarketing.com